In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.

@article{Merchan2003InVA,
  title={In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.},
  author={Jaime R. Merchan and Barden Chan and Sujata Kale and Lowell E. Schnipper and Vikas P Sukhatme},
  journal={Journal of the National Cancer Institute},
  year={2003},
  volume={95 5},
  pages={388-99}
}
BACKGROUND Many antiangiogenic molecules are proteolytically cleaved from larger plasma proteins. For example, plasminogen activators cleave plasminogen into plasmin, and plasmin is converted into angiostatin in the presence of sulfhydryl donors. We thus investigated whether the antiangiogenic activity in plasma could be increased by treatment with recombinant tissue plasminogen activator (rt-PA) and the sulfhydryl donor captopril. METHODS Human plasma was treated with rt-PA (10 micro g/mL… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2002

Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation

B Troyanovsky, T Levchenko, G Mansson, O Matvijenko, L. Holmgren
J Cell Biol • 2001

Functional evaluation of plasmin formation in primary breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2001

Angiostatin and Angiostatin-related Proteins

Cancer and Metastasis Reviews • 2000

Similar Papers

Loading similar papers…